Zobrazeno 1 - 10
of 29
pro vyhledávání: ''
Autor:
Xavier Quantin, Nicolas Girard, Marylise Ginoux, Luc Thiberville, Benjamin Besse, Christelle Clément-Duchêne, P.A. Thomas, P. Mordant, Angela Botticella, C. Le Pechoux, J. Khalifa, Eric Pichon, Thierry Jo Molina, F. Le Tinier, Youssef Oulkhouir, Mallorie Kerjouan, Clémence Basse, Pierre Emmanuel Falcoz, F. Thillays, Virginie Westeel
Publikováno v:
Clinical Lung Cancer
Clinical Lung Cancer, Elsevier, 2021, ⟨10.1016/j.cllc.2021.01.020⟩
Clinical Lung Cancer, Elsevier, 2021, ⟨10.1016/j.cllc.2021.01.020⟩
Introduction Thymomas are rare intrathoracic malignancies that may be aggressive and difficult to treat. Knowledge and level of evidence for treatment strategies are mainly based on retrospective studies or expert opinion. Currently there is no stron
Autor:
Kevin L. Stephans, Sarah M.C. Sittenfeld, Gregory M.M. Videtic, Chandana A. Reddy, Aditya Juloori
Publikováno v:
Clinical Lung Cancer. 22:e360-e365
Introduction We sought to evaluate the safety and efficacy of stereotactic body radiation therapy (SBRT) as salvage treatment for local recurrence after prior surgical resection for non–small-cell lung cancer (NSCLC). Materials and Methods We surve
Autor:
Zhirong Zhang, Feng Li, Lin Yang, Ligong Yuan, Yue Zhao, Qi Xue, Shugeng Gao, Ningning Ding, Jie He, Yushun Gao, Fengwei Tan, Jun Zhao, Shuaibo Wang, Yousheng Mao, Dali Wang
Publikováno v:
Clinical Lung Cancer. 22:e201-e210
Background Lobectomy with systematic lymph node dissection (SND) remains the standard procedure for resectable non–small-cell lung cancer (NSCLC), whereas lobe-specific lymph node dissection (LSND) was reported to have more advantages in perioperat
Autor:
Jeffrey D. Bradley, Michael C. Roach, Christopher Abraham, Cliff G. Robinson, Todd A. DeWees, Sana Rehman, John Nikitas
Publikováno v:
Clinical Lung Cancer. 20:107-116
BACKGROUND: Patients with multiple primary lung cancers (MPLC) increasingly receive multiple courses of stereotactic body radiation therapy (SBRT). We aimed to clarify the efficacy and safety of such treatments. PATIENTS AND METHODS: We reviewed a pr
Autor:
X. Chen, Delan Li, Meichen Li, Xue Hou, Likun Chen, Xiaoxiao Dinglin, Ke Sai, Jing Chen, Kaicheng Wang, Na Wang
Publikováno v:
Clinical lung cancer. 22(1)
Background The treatment options for newly diagnosed non–small-cell lung cancer (NSCLC) patients with 1 to 3 synchronous brain metastases (BM) remain controversial. The current study aimed to comprehensively analyze the characteristics, local treat
Autor:
Morihito Okada, Atsushi Kagimoto, Makoto Fujiwara, Yoshihiro Miyata, Yasuhiro Tsutani, Atsushi Kamigaichi, Takahiro Mimae
Publikováno v:
Clinical lung cancer. 21(6)
Introduction We aimed to determine the feasibility of segmentectomy for radiologically solid-dominant clinical stage IA lung cancer measuring 2.1 to 3 cm (whole tumor size). Patients and Methods Data from 197 patients with radiologically solid-domina
Autor:
Anurag K. Singh, Sung Jun Ma, Yusef A. Syed, Lucas M. Serra, Gregory M. Hermann, Jorge A. Gomez-Suescun
Publikováno v:
Clinical Lung Cancer. 19:e235-e240
To compare the clinical outcomes of patients with early-stage non-small-cell lung cancer (NSCLC) who had undergone either single-fraction (SF) or three-fraction (TF) stereotactic body radiation therapy (SBRT) at a single institution during over 8-yea
Autor:
Takayuki Fukui, Rintaro Ito, Hiroyasu Umakoshi, Shingo Iwano, Koji Kawaguchi, Kohei Yokoi, Shinji Ito, Shinji Naganawa
Publikováno v:
Clinical Lung Cancer. 19:e37-e45
We aimed to determine the concordance between the clinical stage (c-stage) and pathologic stage (p-stage) for patients with small-size lung cancer. Additionally we searched for prognostic factors other than the TNM stage.We retrospectively reviewed t
Autor:
Takashi Ono, Hitoshi Wada, Yoshiomi Hatayama, Katsumi Hirose, Tomonori Yabuuchi, Yoshihiro Takai, Motohisa Suzuki, Masato Hareyama, Tatsuya Nakamura, Yasuhiro Kikuchi, Yusuke Azami, Yuichiro Hayashi, Kanako Kimura
Publikováno v:
Clinical Lung Cancer. 17:427-432
Background The efficacy, toxicity, and prognostic factors of high-dose proton beam therapy (PBT) for peripheral stage I non-small-cell lung cancer were assessed in this retrospective study. Materials and Methods Fifty patients with peripheral stage I
Autor:
Anthony A. Gal, Taofeek K. Owonikoko, Madhusmita Behera, Sungjin Kim, Conor E. Steuer, Suresh S. Ramalingam, Fadlo R. Khuri, Rathi N. Pillai, Gabriel Sica
Publikováno v:
Clinical Lung Cancer. 17:e57-e64
Background Lung adenocarcinoma accounts for almost 60% of non–small-cell lung cancer. According to the 2011 International Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS), and European Respiratory Society (ERS) clas